News
 
Email Page
Axinn Expands IP and Regulatory Practice with Partners David Silverstein and Aziz Burgy
December 16, 2015

Axinn, Veltrop & Harkrider is pleased to announce that David Silverstein and Aziz Burgy have joined the firm as partners in the IP Group.  Mr. Silverstein, who will be based in Axinn’s New York office, previously practiced in-house at Par Pharmaceutical and, prior to that, at major New York firms.  Mr. Burgy, who will be based in Axinn’s Washington, DC office, previously practiced as a partner at Arent Fox LLP.   

"We are excited to have David and Aziz,” said Managing Partner James Veltrop.  “They are highly-regarded attorneys who understand the need to harmonize litigation, regulatory and business strategies.  Their skills in handling complex matters and their deep knowledge of the life sciences industry perfectly complement the areas in which our firm has become a recognized leader." 

Mr. Silverstein has a dozen years of experience handling legal and regulatory matters relating to pharmaceutical and biotech products, having worked on the generic and the brand side.  While in-house, Mr. Silverstein oversaw and managed all aspects of patent, antitrust, unfair competition and trade secret litigation.  He also served as Par’s in-house regulatory counsel, advising on regulatory strategies and frequently representing Par before FDA’s Office of Chief Counsel and other regulators.  

Mr. Burgy has over a dozen years of patent litigation experience, including over 30 pharmaceutical and medical device cases.  He also has extensive experience litigating before the U.S. Patent & Trademark Office.  Mr. Burgy has tried other types of patent cases in U.S. district courts and before the International Trade Commission, including those involving medical devices, Internet security, robotics, software and GPS technology. 

Mr. Silverstein received his J.D. from Duke University School of Law and holds a Master of Chemistry from Cornell University.

Mr. Burgy earned his J.D. at the University of New Hampshire School of Law and holds a Master of Biotechnology from Johns Hopkins University.  Prior to attending law school, he worked at MedImmune, Inc.